drugset / Trial / NCT02459353
Effect of Dapagliflozin on Glycemic Variability
Phase 4
Completed
86 enrolled
The Catholic University of Korea
AstraZeneca · collabEulji General Hospital · collabKyung Hee University Hospital at Gangdong · collabSeverance Hospital · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
Dapagliflozin improves glycemic variability in subjects with type 2 diabetes mellitus when added to insulin therapy. The primary objective of this study is to assess the effect of dapagliflozin on glucose variability compared to placebo after 12 weeks of treatment in type 2 diabetic patients with inadequate glycemic control on insulin.
Timeline
- Start
- 2015-08
- Primary completion
- 2016-12
- Completion
- 2017-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dapagliflozin | Small molecule | 10 mg | — |